Boston Common Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-7,632
| Closed | -$549K | – | 305 |
|
|
2022
Q4 | $549K | Buy |
7,632
+169
| +2% | +$12.7K | 0.03% | 191 |
|
|
2022
Q3 | $531K | Buy |
7,463
+36
| +0.5% | +$2.61K | 0.03% | 191 |
|
|
2022
Q2 | $572K | Buy |
7,427
+590
| +9% | +$44.9K | 0.03% | 198 |
|
|
2022
Q1 | $499K | Sell |
6,837
-958
| -12% | -$64.3K | 0.02% | 214 |
|
|
2021
Q4 | $486K | Buy |
7,795
+410
| +6% | +$24.1K | 0.02% | 212 |
|
|
2021
Q3 | $437K | Buy |
7,385
+8
| +0.1% | +$527 | 0.02% | 214 |
|
|
2021
Q2 | $493K | Buy |
7,377
+485
| +7% | +$31.6K | 0.02% | 218 |
|
|
2021
Q1 | $435K | Buy |
6,892
+1
| +0% | +$62 | 0.03% | 218 |
|
|
2020
Q4 | $427K | Buy |
+6,891
| New | +$424K | 0.03% | 207 |
|
|
2019
Q1 | – | Sell |
-68,383
| Closed | -$3.56M | – | 185 |
|
|
2018
Q4 | $3.56M | Sell |
68,383
-21,766
| -24% | -$1.17M | 0.52% | 68 |
|
|
2018
Q3 | $5.6M | Sell |
90,149
-8,175
| -8% | -$485K | 0.69% | 60 |
|
|
2018
Q2 | $5.44M | Sell |
98,324
-4,481
| -4% | -$242K | 0.67% | 58 |
|
|
2018
Q1 | $6.5M | Buy |
102,805
+1,105
| +1% | +$71.1K | 0.77% | 51 |
|
|
2017
Q4 | $6.23M | Buy |
101,700
+5,061
| +5% | +$317K | 0.74% | 54 |
|
|
2017
Q3 | $6.16M | Sell |
96,639
-290
| -0.3% | -$16.9K | 0.77% | 45 |
|
|
2017
Q2 | $5.4M | Sell |
96,929
-1,355
| -1% | -$73.7K | 0.71% | 56 |
|
|
2017
Q1 | $5.34M | Buy |
98,284
+29,798
| +44% | +$1.63M | 0.73% | 50 |
|
|
2016
Q4 | $4M | Buy |
68,486
+971
| +1% | +$53.1K | 0.58% | 63 |
|
|
2016
Q3 | $3.64M | Buy |
67,515
+15,450
| +30% | +$992K | 0.2% | 136 |
|
|
2016
Q2 | $3.83M | Sell |
52,065
-1,400
| -3% | -$98.9K | 0.22% | 131 |
|
|
2016
Q1 | $3.42M | Sell |
53,465
-565
| -1% | -$35.6K | 0.19% | 140 |
|
|
2015
Q4 | $3.72M | Sell |
54,030
-3,431
| -6% | -$227K | 0.21% | 133 |
|
|
2015
Q3 | $3.4M | Sell |
57,461
-2,675
| -4% | -$170K | 0.21% | 133 |
|
|
2015
Q2 | $4M | Sell |
60,136
-3,550
| -6% | -$234K | 0.21% | 135 |
|
|
2015
Q1 | $4.11M | Buy |
63,686
+330
| +0.5% | +$20.7K | 0.22% | 139 |
|
|
2014
Q4 | $3.74M | Buy |
63,356
+159
| +0.3% | +$8.97K | 0.21% | 142 |
|
|
2014
Q3 | $3.23M | Buy |
63,197
+280
| +0.4% | +$14K | 0.18% | 150 |
|
|
2014
Q2 | $3.05M | Buy |
62,917
+860
| +1% | +$42.4K | 0.17% | 150 |
|
|
2014
Q1 | $3.22M | Sell |
62,057
-1,405
| -2% | -$74.8K | 0.18% | 148 |
|
|
2013
Q4 | $3.37M | Sell |
63,462
-22,625
| -26% | -$1.15M | 0.19% | 142 |
|
|
2013
Q3 | $3.98M | Sell |
86,087
-4,393
| -5% | -$193K | 0.23% | 136 |
|
|
2013
Q2 | $4.04M | Buy |
+90,480
| New | +$3.93M | 0.25% | 131 |
|
Other funds holding BMY
Boston Common Asset Management's BMY Position: Q1 2023 in Review
Boston Common Asset Management sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 7,632 shares — an estimated $549K sold.
Boston Common Asset Management first reported a position in BMY in Q2 2013 and held it in 32 quarters. The position peaked at $6.5M in Q1 2018. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.
- Boston Common Asset Management reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
- Boston Common Asset Management sold 7,632 Bristol-Myers Squibb shares in Q1 2023, an estimated $549K.
- Boston Common Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 32 quarters.
- Boston Common Asset Management's Bristol-Myers Squibb position peaked at $6.5M in Q1 2018.
- 2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.
Based on Boston Common Asset Management's 13F filing for Q1 2023, filed 17 May 2023.